More stimulating news on the medical front added up to gains for bargain-hunting small-cap investors Wednesday.
Oceanside, Calif.-based Therapeutics Solutions International, Inc. (OTC:TSOI) announced the filing of a new patent application, pertaining to the field of cellular therapies, more particularly, to the use of banking of autologous cells, and the manipulation of autologous cells for treatment of one of the more frequently-diagnosed ailments, that of Chronic Traumatic Encephalopathy, or CTE.
Football fans may have heard reports of the recurrence of CTE, caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia.
According to TSOI CEO Tim Dixon, "This new means of obtaining autologous cells and banking them for use in the treatment and prevention of CTE is a new and novel approach.”
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Its shares took off like the proverbial Saturn rocket in Wednesday’s last hour of trade, gathering 9.8% to 45-100ths of a cent, on volume of 5.5 million.
